UNSPSC 51111660: Triciribine

This classification denotes a purine antagonist and inosine monophosphate dehydrogenase inhibitor and amidophosphoribosyltransferase inhibitor with the molecular formula C13H16N6O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2421HMY9N6, chemically known as 1,4,5,6,8-pentaazaacennaphthylen-3-amine, 1,5-dihydro-5-methyl-1-beta-d-ribofuranosyl- (9ci) but generally known as triciribine, which bears US NIH Compound Identifier 65399.

UNSPSC 51111660 Triciribine is a Commodity code covering a specific pharmaceutical active ingredient, but the recent state and local procurement activity tagged under it reflects broader pharmaceutical supply and pharmacy benefit management work rather than direct procurement of triciribine itself. The Texas Health and Human Services Commission issued a Request for Information on April 3, 2026, seeking vendor capabilities for establishing direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers to streamline prescription fulfillment and manage costs. The RFI solicits market intelligence on vendors' experience with direct contracting models for self-insured employers and government health plans, flexibility to negotiate net pricing without rebates, and capacity to implement value-based or outcomes-based pharmacy agreements. This work sits within state health and human services procurement, specifically pharmacy benefit administration and manufacturer relationship management, rather than the procurement of a single active pharmaceutical ingredient.

The single recent opportunity under this code originates from Texas through the state's health agency. The Texas HHS Commission's RFI represents an exploratory, information-gathering phase designed to inform future formal competitive procurement rather than a binding solicitation with award timelines or budget parameters. No set-asides, incumbent contractor designations, or specific funding allocations are identified. The RFI's open design suggests the state intends to solicit responses from a broad vendor base before developing detailed specifications and pricing models for subsequent formal RFP or ITB solicitations. Beyond this single Texas HHS activity, the source provides no evidence of recent state or local procurement activity under this code in other jurisdictions or geographies.